Home
Insights
Team
Contact
Login
Insights: Clients
Healthcare
Pharma Tariffs
Recent/upcoming developments… President Trump has repeatedly indicated an intent to impose tariffs of 25% on pharmaceutical inputs, including in his address to Congress where he laid out his policy agenda. While Trump has been alone in expressing concern about tariffs in sectors such as autos, China hawks have for the last year or so called...
Healthcare
Drug Pricing
President Trump has signed a wide-ranging executive order (EO) aimed at addressing various issues relating to prescription drug pricing.
Financials
,
Macro
China Capital Flows & Restrictions
Treasury Secretary Bessent said in recent days that “everything is on the table” in response to a question about whether the administration would consider de-listing Chinese securities from U.S. exchanges. Doing so has been actively considered by policy makers since President Trump’s first term, alongside other possible restrictions on capital...
Mergers & Acquisitions
Schlumberger/ChampionX
The U.K. Competition and Markets Authority (CMA) announced on April 10 that it had provisionally found the companies' proposed undertakings could address its antitrust concerns. The CMA confirmed they have 40 working days to consider undertakings in more detail, including seeking third-party feedback. We should note that the CMA can extend its...
Mergers & Acquisitions
Rocket Companies Acquisitions (Redfin and Mr. Cooper)
Per the terms of their Merger Agreements, Rocket/Redfin HSR are obligated to file HSR as promptly as practicable following the signing of their deal on March 9, while Rocket/Mr. Cooper is set to file HSR by May 6.
Mergers & Acquisitions
James Hardie/AZEK
Per the terms of the Merger Agreement (MA), the companies are set to file HSR by April 28, 2025.
Pages:
Previous
1
...
29
30
31
32
33
34
35
...
42
Next
↑